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ABSTRACT 
A l11ethod for measuring total plaslua homocysteine was 
developed, giving linearity up to at least 100 umol/L of 
homocysteine, a recovery of 101% and a comparable 
precision to that in published methods. 
~ The method was used for the comparison of pre-and post-
methionine homocysteine levels, and the rise in the 
amino acid after methionine in controls and in patients 
with documented premature vascular disease, because of 
recent evidence suggesting that mild homocysteinaemia, 
i.e. the heterozygote homocysteinaemia, may be similarly 
important to conventional risk factors in the 
development of_premature vascular disease. 
The pre-and post-methionine homocysteine levels and the 
increase in the amino acid after the load were all 
significantly higher in patients than controls as was 
the frequency of post-methionine hyperhomocysteinaemia. 
Post-methionine hyperhomocysteinaemia was of similar 
frequency (28%) to that reported in Western patients (20 
to 40%) while in controls it was slightly higher (4.8% 
versus 1 in 70 to 1 in 200). Although cystathionine~­
synthase could not be measured, the absence of obvious 
liver disease and the infrequency of B12 and folate 
1 
deficiency in the patient group suggest heterozygosity 
for homocysteinaemia as the most likely cause. 
The comparison of the frequency of hyperhomocysteinaemia 
and other risk factors suggested that hyperhomo-
cysteinaemia may be primarily an independent risk factor 






1. 1. 1. Sources of homocys teine and origins of 
deficiency or excess in the human body 
Homocysteine is an essential amino acid not present in 
ingested proteins and is derived from methionine. 
Methionine is obtained both from the diet and by re-
conversion from homocysteine. Both amino acids are 
metabolized in the liver (1). 
Deficiency of homocysteine occurs in protein malnutri tion 
or as a result of a defect in metabolism from methionine 
(1). Since homocysteine is both reconverted into 
methionine and metabolised into cystathionine, the amino 
acid accumulates in inborn or acquired 1errors involving 
either pathway (2). 
3 
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1.1.2 Homocysteine metabolism 
In Figure 1.1 is shown a simplified diagram of methionine 
metabolism (3). Natural protein contains approximately 
0.3 to 5.0% methionine. Some dietary methionine is used 
by the body for tissue protein synthesis, but the 
majority is utilized through the transsulfuration pathway 
to form adenosylmethionine, adenosylhomocysteine, 
homocysteine, cystathionine, t-ketobutyrate, cysteine and 
their derivatives (4). Homocysteine is an intermediate 
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The first step in the transsulfuration pathway is the 
synthesis of S-adenosylmethionine, a reaction catalysed 
by methionine adenosyltransferase (Fig. 1.2) (5). 
coo· H,O PP?I 






















F · 1 2 The synthesis of S~adenosylmethionine from :I- g . . 
methionine 
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S-adenosylmethionine is the principal methyl donor in the 
body. Biologically important compounds that obtain their 
methyl group from S-adenosylmethionine include: creatine, 
choline and phosphatidylcholines, methylated DNA and RNA, 
and epinephrine (4). S-adenosylhomocysteine is formed as 
an intermediary product in this pathway (Fig. 1.3), and 
S-adenosylhomocysteine is then l).ydrolysed to homocysteine 
( 6 ) . 
adenosyl-S·CH:CH2CH .COO· 
I I 
CH 3 NM; 
S-ad:nosylmcthionine 
adenosyl-SCH 2CH 2CH. COO-
I NH; 
admosylhomoeysteinase 0 7' "" ~ HSCH2CH2~H.CO -
HzO. adenosine NHi" 
S-adcDosylbomocysteinc homocysteine 




Under normal circumstances, only small concentrations of 
homocysteine are measurable in human plasma and neither 
homocysteine nor its disulphide homocystine are found in 
urine because of the effective removal of homocysteine by 
4 possible pathways (4,7). 
In pathway 1, homocysteine reacts wi th serine in the 
presence of cystathionine p-synthase (EC 4.2.1.22) to 
form cystathionine. This is an irreversible reaction 
requiring pyridoxal phosphate as a coenzyme (8). Cysta-
thionine is further metabolised to cysteine and ~-keto­
butyrate by another pyridoxal phosphate-dependent enzyme, 
cystathionase. The sulfur atom of methionine, trans-
ferred into the cysteine molecule through the trans-
sulfuration pathway, ends up mainly as inorganic sulfate 










































Formation of sulphate from homocysteine 
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_aFIi"I'_ 
In pathways 2 and 3, homocysteine is remethylated to form 
methionine through two different enzymatic reactions. In 
pathway 2, the methyl group is derived from betaine and 
is catalysed by betaine homocysteine methyltransferase 
(EC 2. 1 . 1 . 5 ) ( Fig. 1 . 5 ) . 
irreversible (5) . 
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Remethylation of homocysteine to L-methionine Fig. 1.5 
through the betaine pathway 
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Pathway 3 requires N5-methyltetrahydrofolate as a methyl 
donor and methylcobalamin (methyl B12 ) as coenzyme. The 
enzyme catalyzing this reaction is 5-methyltetrahydro-
folate-homocysteine methyl-transferase (EC 2.1.1.13) 
(Fig. 1.6). This is the only significant metabolic 








"--./ Homocysteine ___ --.;::::a...........::::;;~--..... Methionine 
S" coenzyme 
Fig. 1.6 Remethylation of homocysteine through 5-methyl 
tetrahydrofolate pathway 
In pathway 4, intracellular homocysteine is released into 
the extracellular fluid (9). 
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1.2 Causes of and clinical syndromes in homocysteinaemia 
Reduction in homocysteine metabolism through either the 
transsulfuration (pathway 1) or the 5-methyltetra-
hydrofolate-dependent suI fur conservation pathway 
(pathway 3) leads to accumulation of the amino acid with 
resultant homocysteinaemia and homocystinuria. The 
biochemical defects concerned include: - deficiency in 
enzymes cystathionine ~ -synthase and 5, 10-methylene-
tetrahydrofolate reductase and defects of cobalamin 
synthesis (10). Defects in pathways 2 and 4 have not 
been described. 
1.2.1 Deficiency of cystathionine 6-synthase 
Cystathionine ~-synthase deficiency is the most 
frequently encountered cause of hyperhomocysteinaemia 
( 11 ) . More than 350 ' cases of proved or presumptive 
cystathionine ~-synthase deficiency have been described. 
It is inherited as a Mendelian recessive trait with 
genetic heterogeneity in expression (2). The patients 
can be divided into two groups depending on their 
12 
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biochemical response to vitamin B6 (12). In one group 
there is partial basal enzyme activity which may improve 
with vitamin B6 administration while in the other there 
is no enzyme activity and no response to vitamin B6 
treatment (13). Vitamin Bb-responsive and vitamin-B6-non 
responsive patients are equally frequent. Bb-
nonresponsive patients have an earlier onset and more 
severe manifestation of their disease than do patients 
responsive to vitamin B6 (7). 
1.2.1.1a Homozygous homocysteinaemia 
The clinical manifestations in homozygous homo-
cysteinaemia differ significantly from those in the 
heterozygous state. 
In the West, the incidence of this autosomal recessive 
metabolic disease is 1:8000 - 1:200,000 (14). In the 
Chinese, the incidence is unknown. 
Clinical manifestations 
Subjects with this disease are normal at birth, but 
develop progressively more severe clinical features from 
13 
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childhood to young adulthood. The eyes and the skeletal, 
central nervous and vascular systems are mainly involved 
( 14 ) . 
Ocular lesions 
Ectopia lentis is common ( 15) . The lenticular 
dislocation takes place between three to ten years of 
age. Subluxation of the lens is often accompanied by 
myopia and iridodonesis and, less frequently, by retinal 
degeneration and detachment, glaucoma and cataracts. The 
ectopic lentis is secondary to disruption of the zonula 
fibers (high content of cystine) that connect the lens to 
the ciliary body. In cystathionine p -synthase 
deficiency, these fibers are thickened and broken (14). 
Skeletal lesions 
Osteoporosis, especially in the spine and long bones, is 
the most consistent skeletal abnormality. Scoliosis ,is 
also frequent, wi th and wi thout osteoporosis. Other 
abnormalities include biconcavity of the vertebrae, 
thought to be due to spinal osteoporosis or to vascular 
occlusion of the vertebral arteries. The patients are 




Central Nervous System lesions 
Developmental delay during the first or second year of 
life is often the earliest clinical feature with 
homozygous cystathionine p-synthase deficiency. Mental 
retardation is common and becomes obvious in middle 
childhood. However, about 20% of patients have normal or 
near normal intelligence. Convulsions, hemiparesis, uni-
lateral weakness and spasticity are frequent and thought 
to be due to cerebrovascular occlusions (I). 
Vascular lesion 
The life expectancy of homozygous homocysteinaemic 
patients is rarely above early middle age, predominantly 
because of premature occlusive vascular disease (7). 
Cardiovascular, cerebrovascular and peripheral vascular 
disease and pulmonary emboli are all common, occurring at 
any age and are the usual ca~se of death. Thrombi and 
emboli are commonly encountered at postmortem examination 
even when they were clinically inapparent. Some other 
clinical features, such as the malar flash and livedo 
reticularis, are also thought to be of vascular origin 
( 1) . 
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Other features 
Cases with hepatomegaly due to fatty changes, electro-
myographic evidence of myopathy, hyperinsulinemia with 
abnormal glucose tolerance and increased levels of growth 
hormone have also been reported (I). 
Diagnosis of homozygous homocysteinaemia 
The presence of one or more typical clinical features may 
lead to a suspicion of cystathionine o -synthase 
deficiency. The most consistent biochemical findings are 
homocystinuria, hyperhomocysteinaemia, hypermethioninemia 
and a markedly reduced concentration of serum/plasma 
cystine. The confirmatory test is the demonstration of 
severe reduction in activity of cystathionine ~-synthase. 
The activity of the enzyme can be assayed in liver biopsy 
specimens, cultured phytohemagglutinin-stimulated lympho-
cytes, and in cultured skin fibroblasts (2). However "in 
some patients the cystathionine p-synthase activity is 
within the control range (1). In such cases the 
diagnosis remains presumptive and is based on the 
clinical features and the presence of homocystinuria, 
hyperhomocysteinaemia and hypermethioninemia. 
16 
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1.2.1.1b Heterozygous hyperhomocysteinaemia 
In the general 
thought to be 1 
Western population, the incidence 
in 70 to 1 in 200 or less (16). 
is 
In 
patients with early vascular disease , it is 20% to 40% 
(17-20). The prevalence in the Chinese is unknown. 
Clinical manifestations 
Heterozygous homocysteinaemia does not give ris~ to any 
abnormal somatic features as seen in the homozygous 
state. However, although the association of premature 
vascular disease with severe homocystinaemia, such as in 
the homozygous cystathionine ~-synthase deficiency is 
well known, in recent years an association with mild 
homocysteinaemia, detected either in the fasting state or 




Biochemical abnormalities in heterozygous 
homocysteinaernia 
In the heterozygotes, there is no excessive homocystin-
uria and in the fasting state the plasma/serum homo-
cysteine concentrations are normal or slightly increased. 
However, after methionine loading, the homocysteine 
concentrations increase more than in unaffected 
subjects, indicating that the activity of cystathionine 
~-synthase, in the presence of excess methionine, is 
inadequate. 
Identification of Heterozygotes 
1) Cystathionine ~ -synthase can be assayed in liver 
biopsy samples, cultured fibroblasts and phytohem-
agglutinin-stimulated lymphocytes. These assays detect 
most heterozygotes as the mean specific activity is less 
than 50% of the mean control specific activi ty. Howev~r, 
some obligate heterozygotes have enzyme activity within 
the control range. Therefore, the above methods can 
detect some but · not all heterozygotes (21) and the 




2) Methionine loading test 
After methionine loading, plasma/serum homocysteine 
levels in heterozygotes increase more than in tnorma~ 
controls. This serves as a diagnostic test (19). Oral 
methionine loading is a recent investigative procedure. 
A physiological substance is used and side effects have 
not been recorded (19). 
However, the reference range for the fasting and post-
methionine homocysteine levels and the expected rise in 
homocysteine after methionine loading in the normal 
population and in the heterozygotes for homocysteinaemia 
have not been fully evaluated. In most studies to date, 
the levels in patients with vascular disease had to be 
compared with those in control subjects investigated at 
the same time (19). 
Further, not all cases of hyperhomocysteinaemia are due 
to the heterozygous state, thus finding higher post 
methionine level than controls only suggests hyperhomo-
cysteinaemia, but does not fully differentiate the 
heterozygous state from other causes of hyperhomo-
cysteinaemia, such as B12 or folate deficiency, although 
in the former the homocysteine levels tend to be much · 
higher. 
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1.2.2 Deficiency of 5,10 methylenetetrahydrofolate 
reductase 
Deficiency of 5, 10-methylenetetrahydrofolate reductase is 
a rarer cause of hyperhomocysteinaemia wi th only 25 
patients, from 20 families, having been reported to date 
(22). The relationship of this enzyme to homocysteine 
metabolism is illustrated in Fig. 1.6 (see above). The 
inheritance pattern appears to be autosomal recessive, 
but thermal stability studies have suggested possible 
allelic variations (23). 
Clinical features 
The usual clinical manifestations include neurological 
dysfunction with delayed psychomotor development, severe 
mental retardation and psychiatric symptoms, seizures and 
peripheral neuropathy (24) .. Vascular complications are 
uncommon. These symptoms are quite different from homo-
cysteinaemia due to cystathionine r-synthase deficiency. 
However, three patients suffering from recurrent strokes 
and pulmonary emboli have been reported to have 5,10-
methylenetetrahydrofolate reductase deficiency, 
indicating that this type of hyperhomocysteinaemia may 
also be associated with occlusive vascular disease (22). 
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Diagnosis of 5,10 methylenetetrahydrofolate reductase 
deficiency 
In patients with homocysteinaemia due to 5,10-methylene-
tetrahydrofolate reductase deficiency, the characteristic 
biochemical changes are moderate homocystinuria and 
homocysteinaemia, with relatively normal level of plasma 
methionine. The enzyme activity can be readily assessed 
in hepatocytes, fibroblasts, lymphocytes and leucocytes 
( 1 ) . 
1.2.3 Defects of cobalamin synthesis 
The folate-dependent methylation of homocysteine (pathway 
3) requires methylcobalamin as a cofactor. Deficient 
synthesis of methylcobalamin resul ts 
anaemia, homocysteinaemia and a 
in megaloblastic 
low or normal 
concentration of methionine in plasma. Patients wi th 
deficient synthesis of both adenosylcobalamin and 
methylcobalamin have in addition, methylmalonic acidemia 











I 1 CHz -COSC.cA 
ADENOSYLCOBALAMIN 
---~~~-..;;...~----;~~ Svccinyi - CoA 
Mutase , 
Fig. 1.i Reactions catalyzed by cobalamin coenzymes 
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1.3 Standardised oral methionine load test 
Homocysteine is either metabolised to cystathionine, 
remethylated to methionine or exported from the cells 
unchanged. The distribution of metabolism between these 
pathways is determined by the enzyme concentrations and 
their Km for homocysteine, and the regulating effects of 
adenosylmethionine. Under normal conditions the 
metabolising and remethylating pathways are balanced and 
little unchanged homocysteine is exported from the cells 
( 9 ) . 
The homocysteine catabolising enzymes are activated by 
increased levels of adenosylmethionine in response to 
raised dietary levels of methionine, resulting in 




adenosylmethionine also inhibi t methionine 
catabolism rather than reconversion to 
., 
is favoured. However, more unchanged 
homocysteine also diffuses out of the cells. In the 
presence of reduced levels of intracellular methionine, 
homocysteine is reconverted preferentially to methionine 
rather than metabolised to cystathionine or allowed to 
23 
diffuse out, unless the activity of methionine synthetase 
is reduced (9). 
The effects of low and high intracellular concentrations 
of methionine on the homocysteine levels in blood form 
the basis of the standardised oral methionine load test, 
used in clinical practice to detect hyperhomo-
cysteinaemia. In the fasted state the activity of 
methionine synthetase is increased and unless the enzyme 
is deficient or there is cobalamin or folate deficiency, 
the plasma/serum homocysteine levels are low. At high 
methionine concentrations, the activity of cystathionine 
synthase increases, thus limiting the amount of 
homocysteine diffusing out of the cells unmetabolized. If 
the activity of the enzyme is reduced, as in homozygous 
or obligate heterozygotes, the plasma/serum homocysteine 
levels increase 'abnormally'(9). 
24 
1.4 Treatment and prospects for homocysteinaemia 
1.4.1 Homozygous homocysteinaemia 
Management of patients with homocystinuria due to 
cys~athionine r -synthase deficiency includes dietary 
Uleasures, administration of pyridoxine, specific drug 
therapy and treatment of clinical complications. 
Whenever possible, treatlnent should begin before clinical 
complications occur, since many are irreversible. Even 
before clinical effects are recognizable, tissue damage 
may occur. Thus maximal benefi t is thought to be 
obtained if treatment is instigated as early as possible 
in the neonate (14). 
Diet 
Diets specifically low in methionine and supplemented 
with L-cystine are designed to reduce the accumulation of 
methionine, homocysteine and their metaboli tes. The 
progressive complications of cystathionine f)-synthase 
deficiency may be prevented or alneliorated with low 
methionine diets supplemented with cystine (26). 
25 
Administration of choline (27), a precursor of the methyl 
donor betaine, or betaine itself results in lower homo-
cysteine and higher methionine concentrations. In some 
patients, treatment with folate may help while in others, 
therapy with folate in combination with vitamin B12 and 
pyridoxine lowers homocysteine levels with little or no 
increase in the methionine concentration (28). 
Administration of Pyridoxine 
In vitamin B6 responsive cystathionine ~ -synthase 
deficient patients, treatment wi th vi tamin B6 reduced the 
incidence of vascular events (29). The apparent efficacy 
of the treatment with vitamin B6 highlights the 
importance of identifying hyperhomocysteinaemia in 
patients with vascular disease particularly if other, 
more common risk factors are absent. 
Specific Drug Therapy 
Antithrombotic therapy with dipyridamole has been tried 
but its efficacy is not certain (30). Avoidance of 
factors associated with an increased risk of thrombo-
embolism such as the use of oral contraceptives has also 
been suggested (31). 
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Treatment of clinical complications 
The treatment of clinical complications is the same as 
when due to other causes. An important exception, 
however, is the need for avoidance of surgery because of 
the risk of thromboembo1i post-operatively (l). 
1.4.2 Heterozygous homocysteinaemia 
In some heterozygotes complete normalization of the post-
methionine loading homocysteine levels occurs following 
treatment with Vitamin B6 at a dose of 250 mg daily. 
Normalization has also been reported after treatment with 
betaine or folic acid at a dose of 6 g or 5 mg daily 
respectively (16,32). 
Homocysteine lowering treatment, in particular when 
started early, was shown to prevent a number of serious 
clinical sequelae in patients with homozygous 
homocysteinaemia. The clinical relevance of such therapy 
in heterozygous arteriosclerotic patients, in terms of 
prevention of progression of the arteriosclerotic lesions 
or reduction in the number of recurrent thromboembolic 
events, has, unlike in homozygous, not yet been 
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demonstrated. If further studies establish such a 
beneficial clinical effect, then it will become important 
to screen patients with premature vascular disease, 
particularly if the usual risk factors for arterio-
sclerosis are absent, for heterozygosity for 
homocysteinaemia (33). 
1.5 Pathogenesis of vascular disease in homocystinuria 
The precise cellular and molecular mechanisms that might 
link vascular disease with hyperhomocysteinaemia, whether 
mild or severe, are not yet certain and various 
suggestions have been made. 
Firstly, thromboembolic tendencies in homocysteinaemia 
are thought to be consequent on conversion of methionine 
to homocysteine thiolactone, the latter being the 
reactive cyclic internal lactone of homocysteine. The 
free amino groups of low density lipoprotein (LDL) are 
thiolated by homocysteine thiolactone, causing 
aggregation and increased uptake of LDL by macrophages 
and therefore lipid deposition in atheromas. 
Homocysteine thiolactone, released from homocysteinylated 
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LDL within the vascular wall, promotes intimal injury, 
oxidation of cholesterol and unsaturated lipids, platelet 
aggregation, myointimal hyperplasia, deposition of 
sulfated glycosaminoglycans, fibrosis and calcification 
of atherosclerotic plaques (34). 
Secondly, hyperhomocysteinaemia has also been reported to 
inhibit the expression of thrombomodulin and to 
inactivate both thrombomodulin and protein C 
irreversibly, leading to decreased protein C activity. 
It has been suggested that a synergistic interaction 
between the effects of the reactive homocysteine 
metabolites on the vascular endothelium and protein C 
deficiency may be a reason for premature thromboembolism 
( 35) • 
Thirdly, excess homocysteine is also thought to ini tiate 
coagulation by the tissue factor pathway through, a 
mechanism involving the free thiol group of the amino 
acid and by tissue factor gene transcription (36). 
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1.6 Aim of the study 
In the Hong Kong population, the incidence of the 
heterozygous homocysteinaemia is unknown. Thus, the aims 
of the study are: 
(1) To validate a known or establish a modified 
method for homocysteine measurement in plasmal 
serum. 
(2) To measure homocysteine concentration before 
and after methionine loading in patients with 
documented premature vascular disease and in 
controls of similar age group. 
(3) To examine, if there is an interaction between 
homocysteinaemia an? conventional risk factors 
for vascular disease such as hyperlipidaem~a, 
hypertension and smoking. 
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CHAPTER TWO 
Patient and control selection and the methionine loadi~g 
test 
The following are a set of criteria that the patients and 
controls had to fulfil to be included in the study. 
2.1 Patient's criteria: 
1. , Either sex 
2. Age 60 years or less at the time of diagnosis 
3. Myocardial infarction or ischaemia (angina) 
confirmed by electrocardiography and/or 'cardiac 
enzyme changes, and in all, by coronary angiography. 
4. As the effect of acute illness on methionine is not 
well understood, patients were investigated at least 





2.2 Control's criteria: 
1. Either sex 
2. Age 60 years or less 
3. Free of overt disease 
2.3 Exclusion criteria for patients and controls: 
1. Age above 60 years at the time of the first 
admission and diagnosis of vascular disease 
2. Diabetes mellitus 
3. Overt renal, hepatic, thyroid or metabolic disease 
4. Acute or severe systemic illness within the previous 
3 months 
5. Cardiovascular disease not due to atherosclerotic 
obstruction of coronary vessels 
6. Use of nitrous oxide within past 3 months 
7. Known cardiomyopathy 
8. Psychiatric illness 
9. Anti-epileptic medication 
10. Pregnancy 
11. Chronic alcohol abuse 
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Hyperlipidemia, smoking and hypertension were not 
exclusion criteria in our study as part of the study was 
to examine the interaction of homocysteinaemia wi th these 
risk factors. The presence of additional, peripheral or 
cerebrovascular disorders was not an exclusion criteria 
either. 
2 . 4 The methionine loading test and additional 
investigations carried out 
1) After an overnight fast (water, black coffee and tea 
were allowed), the following were noted: age, sex, 
date of last menstrual period, smoking habit, 
medication (vitamin supplementation and the 
contraceptive pill which may alter metabolism and 
al though not exclusion cri teria, were recorded), 
weight and blood pressu~e. 
2) 45 ml of blood was taken for measuring haemoglobin, 
haematocrit, white cell count, urea, creatinine, 
sodium, potassium, bilirubin, free T4 and TSH, total 
serum and red . blood cell folate, pre-load 




concentrations and the activities of SGOT, GGT and 
alkaline phosphatase. 
3) L-methionine was given in an oral dose of 0.1 g/kg 
body weight together wi th a methionine-free 
breakfast provided by the hospital dietitian. 
Later on, 
provided. 
a methionine-free lunch was also 
Water, coffee and tea without milk 
and orange juice were allowed ad lib. 
4) Six hours after the load, the blood pressure 
was measured again and 10 ml of blood was taken 
for homocysteine measurement. 
Blood samples for homocysteine measurement were processed 
as mentioned in chapter three, section 3.1. The 
haematological and biochemical tests were performed in 
the Pathology Unit of Prince of Wales Hospital according 
to the routine laboratory practice. 
The haematological and biochemical tests carried out were 
necessary as a profile of general health. The 
haematological examination and the B12 and folate 
concentrations were necessary to exclude megaloblastic 
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anaemia (the vitamins are cofactors for homocysteine 
metabolism) and the liver function tests to exclude liver 
disease (which can cause acquired hyperhomocysteinaemia) . 
The thyroid function tests were carried out to exclude 
subclinical thyroid disease, the general effects of which 
may include abnormalities in homocysteine metabolism. 
Fasting lipids were measured because they are a risk 
factor for ischaemic heart disease. 
It was thought that the prospect of methionine loading, 
a relatively unpalatable diet following, venepuncture and 
a several hour stay at the hospital could affect the 
blood pressure particularly when initially measured. 
Thus two sets of reading were taken, one just before the 
first venepuncture and methionine load and the other at 
~he end of the test, when any earlier riie would have 
been expected to have normalized if the 'subject was not 
hypertensive. 
2.5 Statistics used for data analyses 
The subjects' results were expressed as the mean and 
standard deviation (SO). The difference between the 
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fasted and post-methionine homocysteine levels, i.e. the 
response to methionine was calculated for each patient 
individually. 
The fasting and post-methionine homocysteine levels and 
the response to methionine between controls and patients 
were compared using the Mann Whitney test because of the 
non-Gaussian distribution, before and after removal of 
the controls whose homocysteine levels were above the 
mean + 2, 2.5 and 3 SD and recalculating the mean. The 
other haematological and biochemical indices between the 
two groups were compared using the Student's t test. 
The frequency of hyperhomocysteinaemia in patients and 
controls was compared using the Chi square Fisher's Exact 
test. The frequency of hyperlipidaemia, hypertension, 
smoking, the sex distribution, B12 and folate deficiency 
between controls and patients and between patients with 
and without hyperhomocysteinaemia was also carried out 
using the Chi square Fisher's Exact test, but after 
removing the controls with hyperhomocysteinaemia in the 




Abnormal results were defined as those above the 
recalculated control mean+2. 5 SD. Moreover, for ·the 
frequency distribution of hyperhomocysteinaemia in 
controls and patients, the data using the control mean+2 
and 3 SD are also shown. An abnormal rise in 
homocysteine after methionine was termed methionine 
intolerance 
tolerance. 
or abnormal/pathological methionine 
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CHAPTER THREE 
3.1 Sample collection 
Total homocysteine concentration in whole blood increases 
rapidly to a value in excess of 180% of the basal 
concentration if whole blood is left for several hours 
prior to processing. Methionine continues to be 
metabolised to homocysteine in the stored red blood cells 
after venepuncture if left at ambient temperature. The 
concentration is also affected by sunl-ight (UV light). 
Therefore blood samples after venepuncture were stored on 
ice, in the dark and usually the plasma was separated 
from the red cells as soon as possible after collection 
(37). Heparin and EDTA samples have both been used (38). 
If plasma/serum are kept at -20oC~ they can be stored for 
up to ten years before analysis (39). 
In this study, after venepuncture, 10 ml of blood was 
aliquoted into a plastic bottle containing heparin (0.2 
mg/ml), immediately put on ice in a thermal flask which 
was tightly shut to exclude sunlight, the sample was 
transported to the laboratory as soon .as possible, 
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centrifuged (at room temperature) and the separated 
plasma stored at -70°C until analysis. 
3.2 Analytical methods for homocysteine determination 
Urine homocystine measurement 
3.2.1 Cyanide nitroprusside test 
The cyanide nitroprusside test is an old established 
screening test for excess homocysteine in urine. 
Ni troprusside combines wi th sulphur containing amino 
acids to produce a red c'olour after the reduction of 
disulphide bonds by cyanide ( 40) • Since this test 
detects most disulphides, it may be positive in other 
inborn errors where excess disulphide is excreted such as 
in cystinuria and ~-mercaptolactate cystinuria (1). 
Further, an artifactual form of homocystinuria can occur 
through bacterial conversion of cystathionine to 
homocysteine. This has been described in urine 
contaminated with massive cystathionine (11). 
A modified cyanide-nitroprusside test is also available 




homocystine. With the addition of silver nitrate, only 
homocystine reacts to give a magenta colour (41). 
However, the lack of sensitivity and the labile nature of 
the colour has restricted the use of this assay. 
Plasma/serum homocysteine measurement 
In plasma/serum, almost all homocysteine is in the 
disulfide for~--either bound to albumin (70-80%) or to 
low-molecular-mass sulfhydryls, mainly cysteine (20-30%) .. 
Only traces are found in the free form (42). Usually 
total homocysteine is measured. Thus, in most reported 
methods, the analytical steps include reduction to 
disassociate the amino acid from proteins, protein 
precipitation, centrifugation and the measurement of the 
total homocysteine in the supernatant. 
3.2.2 Radioenzymic Assays 
Total homocysteine in plasma/serum has been measured with 
a radioenzymatic assay based on the conversion of 
homocysteine to S [ 14 C] -adenosylhomocysteine in the 
presenc;e of [ 14 C] -adenosine and S-adenosylhomocysteine 
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-hydrolase, after reduction with dithioerythritol. Protein 
is precipi tated wi th perchloric acid. The radioactive s-
[l~C]-adenoSYlhomocysteine is iaolated by reversed phase 
high performance liquid chromatography and quantitated by 
liquid scintillation counting (43). 
A modification of the method where S-[14C]-adenosyl-
homocysteine is adsorbed on a paper chromatograph and the 
radioactivity of the isolated spot is counted by a 
scintillat~r, has also been described (44). 
The radioenzymic techniques are sensitive and specific 
and are used to measure homocysteine in both blood and 
urine. The modification based on paper chromatography 
requires inexpensive equipment. However, this technique 
involves several tedious manual procedures and cannot be 
easily automated. 
3.2.3 Gas chromatography-Mass spectrometry 
In this method, a deuterated internal standard is added 
to serum followed by 2 mercaptoethanol. After heating at 
400C for 30 minutes, protein is precipitated with 
41 
III 
sulfosalicylic acid and the supernatant is partially 
purified by sequential cation exchange and anion exchange 
chromatography. After drying, the supernatant is 
derivatized with N-methyl-N-(tert-butyl dimethylsilyl) 
trifluoroacetamide. The tert-butyl dimethylsilyl 
derivatives 'are separated and quantified by capillary GC-
MS with selected ion monitoring (4S). Deuterated 
homocysteine is added as internal standard to correct for 
the variable recovery through the many steps and the 
reoxidation of homocysteine during sample processing. 
This method offers high sensitivity and specificity and 
can measure homocysteine in urine as well as in blood. 
The major disadvantages are th~ relative high cost of the 
equipment and the many manual steps involved which cannot 
be automated easily. 
3.2.4 HPLC with Electrochemical detection 
After reduction wi th sodium borohydride (NaBH4) and 
protein precipitation with perchloric acid, thiols in 
plasma/serum, including homocysteine are detected in the 
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column effluent by a single gOld-fuercury electrode (9). 
The chromatographic system can be modified to resol~e 
cysteine, homocysteine- and cysteinylglycine. The 
attractive features of this electrochemical assay 
include: simple 'sample processing, short run time, large 
sample throughput, specificity and the possibility of 
determination of other thiols such as cysteine. 
The major disadvantages are the long equilibration time 
before the detector becomes stabilized, flow cell 
contamination and deterioration of the gold-mercury 
electrode. 
3.2.5 HPLC and postcolumn derivatization 
Total homocysteine in plasma/serum can be measured with 
the conventional amino acid analyser. The 'plasma/serum 
samples are reduced wi th di thiotrei tol, proteins are 
precipitated with sulfosalicylic acid and ninhydrin is 
used as the staining reagent (46). Analysis of 
homocysteine with a conventional amino acid analyser has 
several advantages such as simple sample preparation and 
apparatus which is relatively easy to operate. The main 
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-drawback is the nonselectivity for sulfur containing 
amino acids, and therefore it needs good chromatographic 
conditions for separation of peaks. 
Another assay using post-column deriva-tization involves 
reduction of plasma/serum samples with dithiotreitol and 
protein precipitation with sulfosalicylic acid. 
Separation is carried out with reversed phase ion-pair 
liquid chromatography, post-column derivatization with 
4,4'-dithiodipyridine and colorimetric detection of the 
product, formed between 4,4'-dithiopyridine and 
homocysteine, at 324 nm. The detection limi t of this 
method is < 50 nmol/l (47). The method gives high 
precision and better sensitivity than other HPLC methods 
owing to the high absorbance coefficient. However, there 
is significant baseline fluctuation, although this can 
be minimized by using pulse dampers and keeping 4,4'-
di thiodipyridine at oOe. 
3.2.6 Precolumn derivatization, HPLC and fluorescence 
detection 
In this method monobromobimane has been used for 
determining homocysteine in plasma/serum and sodium 
44 
borohydride as a reductant. Excess fluorescent 
monobromobimane is removed by treating the sample with 
thiol Sepharose and the sample is then extracted by solid 
phase extraction (48). However, thiol Sepharose 
treatment and solid phase extraction are tedious 
procedures. 
Recently, a fully automated method for the determination 
of plasma homocyste f ne based on sodium borohydride 
reduction and derivatization with monobromobimane has 
been developed ( 39) . Baseline separation of 
homocysteine, cysteine and cysteinylglycine is obtained 
by eluting the column with an ammonium formate buffer 
adjusted to pH 3.65. 
Another thiol-specific fluorogenic reagent, ammonium 7-
fluorobenzo-2-oxa-l,3-diazole-4-sulphonate (SBD-F) has 
been used as derivatizing reagent. Thiols derivatized 
with SBD-F are reported to show high fluorescence, SBD-F 
itself is non-fluorescent and no fluorescent byproducts 
are formed during the derivatization procedures. 
Homocysteine, cysteine· and cysteinylglycine adducts are 
separated by gradient elution from a reversed-phase 
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column and detected by a fluorescence detector (50). The 
separation of the eluents can be speeded up from the 16 
minutes with gradient elution to 12 minutes with the use 
of isocratic elution without affecting separation (49). 
However, the low pH of the mobile phase with isocratic 
elution increases dissolution of the silica-matrix, thus, 
shortens the life span of the column. This can be 
circumvented with the use of a guard column behind the 
injector. The precision of this method can be improved 
by including mercaptopropionylglycine as internal 
standard to correct for inaccurate composition of the 
assay mixture and/or variable injection volume (50). 
The SBD-F based methods are sensitive and specific and 
there are no interfering reagent peaks in the 
chromatogram. Disadvantages include low reactivity of 
SBD-F and prolonged reaction time at a high temperature 
(600C, 1 hr) which can destroy some of the thiols being 
measured but does not affect homocysteine. 
Recently, 7-fluorobenzo-2-oxa-l,3 diazole-4-sulfonamide 
(ABDF) has been introduced as derivatizing agent. It 
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reacts faster than SBD-F and at a lower temperature (51). 
Shorter reaction time and. lower temperature lead to less 
destruction of some biological thiols. With. an isocratic 
mobile phase, a 7-8 minutes 
obtained. 
retention time can , be 
Total plasma/serum homocysteine has recently been assayed 
with precolumn derivatization with o-phthaldialdehyde 
followed by HPLC and fluorescence detection (52 & 53). 
Plasma/serum is reduced with 2-mercaptoethanol and 
homocysteine is carboxymethylated with iodoacetate before 
derivatization wi th o-phthaldialdehyde. Homocysteic acid 
is used as internal standard. The method gives good 
sensitivity and precision. The widespread experience 
with the o-phthaldialdehyde techniques and the possible 
determination of other aminothiols and amino acids 
(including cysteine and cysteinylglycine) are other 
attractive features. 
3.3 The method used in this study 
The method for total homocysteine measurement in this 
project was based on those of Ubbink et al. (49) and 
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Jacobsen et al. (48) with some modifications. The method 
includes ' reduction of the plasma sample wi th sodium 
borohydride (48), protein precipitation wi.th 
SBD-F, trichloroacetic acid, derivatization with 
separation by reversed phase HPLC with an isocratic 
mobile phase (49) and the use of N-2 mercaptopropionyl 







N-2 'mercaptopropionyl glycine, 
Trizma Base and Trizma HCL 
(all from Sigma Chemical Co. ,St. louis, USA) 
Sodium b orohydride (BDH, Poole, UK) 
Sodium hydroxide (BDH, Poole UK) 
Ammonium acetate (Merck AG, Darmstadt, Germany) 







O. 042g NaBH4 in 10 ml 50 mM Tris HCL buffe-r, pH 
9.0, to give a final concentration of NaBH4 
of 0.11 mol/L 
10 % TCA containing 1 mmol/L EDTA 
1.55 mol/L NaOH 
0.125 mol/L borate buffer containing 4 mmol/L 
EDTA, pH 9.5 
SBD-F 1 mg/ml in 0.125 mol/L borate buffer 
without EDTA 
400 mmol/L N-2 mercaptopropionyl glycine 
Instrumentation 
The analysis was performed on a Hewlett Packard HP 1090 
Liquid Chromatograph wi th a HP RP18 5 tnn 200x4. 6 mm 
column protected by a C18 5 urn 20x4 mm id aDS guard 
column. The fluorescence intensities were measured with 
excitation at 385 nm and emission at 515 nm using a HP 
1049A fluorescence detector. The detector signal was 
recorded by a HP 3396A iritegrator. 
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3.3.4 Sample preparation 
3.3.4.1 Reduction 
200 ul thawed plasma was pipetted into a 1.5 ml snap-cap 
Eppendorf tube. 100 ul freshly prepared 0.11 M sodium 
borohydride in SO mM Tris-HCL, pH 9.0 was added. The 
vial was capped, mixed on a vortex mixer for 1 minute and 
incubated at 30°C for 30 mins . . After incubation, 200 ul 
of cold 10% TCA- lmM EDTA was added to precipitate the 
protein. The sample was well mixed on a vortex mixer for 
2 minutes and left at room temperature for 10 minutes. 
The vial was centrifuged at 10,000 rpm for 3 minutes. 
3.3.4.2 Derivatization: 
100 ul clear supernatant was added .to a mixture of 20 ul 
1.55 M sodium hydroxide, 250 ul of 0.125 M borate buffer 
(pH 9.5) containing 4 mM EDTA, 100 ul of SBD·-F (1 mg/ml 
dissolved in borate buffer without EDTA) and 5 ul of 400 
UM N-2 mercaptopropionyl glycine, in an Eppendorf tube. 
The mixture was mixed for 30 seconds on a vortex mixer 
and then incubated for 1 hour at 60°C with constant 
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shaking in a water ' bath, for derivatization of 
homocysteine to take place. After incubation, the tube 
was put on ice until analysis. 40 ul of the derivatized 
sample was injected. 
3.3.5 Chromatographic conditions 
The mobile phase was 0.1 M ammonium acetate buffer with 
5% acetonitrile pH 3.27 (SO ml of acetonitrile in 950 ml 
of 0.1 M ammonium acetate buffer, pH was adjusted with 
glacial acetic acid). The flow rate was 1.3 ml/min at a 
temperature of 43°C. 
3.3.6 Standard preparation 
Stock standard 1 mM was prepared by adding 0.01352 g of 
homocysteine powder in 100 ml deionised water and was 
diluted with deionised water to give working standards 
with concentrations of 100, 200, 300, 400, 500, 600 and 
800 umol/l. 40 ul of a working standard was added to 360 
ul of normal pool serum and assayed as patient sample. 
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-3 .'4 Method Optimization 
3.4.1 Choice of reducing agent 
3.4.1.1 Dithiotreitol (DTT) 
Dithiotreitol (46,47) was first tried as reducing agent. 
O. 5 ml plasma was added to a mixture of 100 ul 0.2 M 
sodium tetraborate pH 8.3 (47) and 25 ul 0.8 M 
dithiotreitol in distilled water, and was incubated at 
37°C for 20 mins for derivatization to occur. 
The thiol group of dithiotreitol also takes up the 
fluorogenic dye and in our chromatograph gave late 
eluting and very large and long peaks which took 20 
minutes to return to the baseline. As column switching 
was not possible on our instrument, DTT was thought not 
to be a sui table reducing agent and was abandoned. 
(chromatogram 1). 
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(.115 
Chromatogram 1. Use of DTT as reducing agent 
3.4.1.2 Sodium borohydride 
In the method of Jacobson D. W. et al. (48), sodium 
borohydride has been used as reducing agent. The 
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efficacy of sodium borohydride as a reducing agent had 
. proved good as in samples stored at -25°C for one week, 
no homocysteine peak was detected when no reduction had 
taken place, whereas homocysteine was detected when 
reduction was carried out with a recovery of 101%. 
Further, sodium borohydride did not form peaks likely to 
interfere with houlocysteine measurements, nor did it 
prolong the running time (chromatogram 2a and 2b). 
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Use of NaBH4 as reducing- agent 
2a. With reduction 
2b. ·No reduction 
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3.4.2 Choice of precipitating reagent 
In order to . avoid binding of protein to the column, 
protein from which homocysteine had been removed ' by 
reduction, had to be precipi tated as thoroughly as 
possible. Methanol, ethanol and acetonitrile had 
all been tried but the precipi tation was incomplete. 
With the addition of 10% TCA into the supernatant, 
protein precipitated further. 10% TCA precipitated 
protein from plasma completely and was used for 
precipitation. 1 mmol/L EDTA was added to the TCA 
solution to prevent oxidation of homocysteine (42). 
3.4.3 Optimization of chromatographic conditions 
3.4.3.1 Flow rate, temperature and organic composition 
of mobile phase 
In order to shorten the analysis time, 6% acetonitrile 
o 
with a flow rate of 1.5 ml/min at a temperature of 45 C 
was tried, but this resulted in incomplete resolution of 
the homocysteine peak (chromatogram 3). The conditions 
were changed to 5% acetonitrile with a flow rate 1.3 
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ml/min at a temperature of 43°C. Complete resolution of 
homocys teine was achieved. It took 8 mins for the 
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Chromatogram 3. 
.J =-s;: i.e;38 .,.,. 
;. ~-... ~ .. ;;::t:;, 2 • ;2 6 4 ~ Homocyste ine peak 
2.~ ·~e 
4.515 
Incomplete resolution of homocysteine 
peak (6% acetonitrile, flow rate 1.5 
ml/min, temperature 45°C) 
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STCIF' 
Chromatogram 4. 
2. ! 55 
2.:£-23 .. (-- Homocysteine peak 
2.9t?5 
Internal standard 
Complete resolution of homocysteine 
peak (5% acetonitrile, flow rate 1.3 
mIlL, temperature 43°C) 
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3.4.3.2 pH of the mobile phase 
Complete resolution was achieved with the pH of the 
mobile phase of 3.27. With more alkaline mobile phases, 
there was incomplete resolution of the homocysteine peak 
(chromatogram 5). 
< Homocysteine peak 
r 
pH = 3.50 
2. ,:. 31 ~(---------- Homocysteine peak 
'---.:===---
pH = 3.27 
Chromatogram 5. Effect of pH on peak separation 
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3.4.4 Confirmation of homocysteine peak 
The homocysteine peak was confirmed by comparing the 
retention .time of homocysteine standards with those in 
plasma samples . and also by co-eluting a mixture of 
standard and sample. 
3.5 Analysis of results 
The standard curves were plotted as the ratio of the peak 
height of homocysteine over that of the internal standard 
versus concentration of homocysteine. The homocysteine 
concentrations in patient and control plasma samples were 
determined from the graph. 
3.6 Method validation 
3.6.1 Linearity 
Stock homocysteine standard was diluted to give a series 
of working standard concentrations as shown in Table 3.1. 
10 ul of working standards were added to 90 ul plasma and 
the analytical procedure was identical to that used in 
patient and control plasma. 
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100 200 400 600 800 1000 
Standard (uL) 100 200 400 600 800 1000 
(1000 umol/L) 
D.W. ( uL) 900 800 600 400 200 0 
D.W. = Deionized water 
Table 3.1 Preparation' of working standard 
In' figure 3.1 is shown a typical standard curve. A 
linear relationship (r=0.99S, y=0.0193x-0.0692) was 
observed between the peak height ratios of homocysteine 
to 2-mercaptopropionyl glycine and the concentrations of 
homocysteine standard in human plasma. 
The linearity range of this method was up to at least 100 
• 
umol/L. This was higher than the highest expected plasma 
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Precision was done by spiking different concentrations of 
standard to plasma to give final concentrations of 20, 60 
and 80 umol/L respectively and assayed as patient 
samples. 
Table 3.2 shows the results of within-run and between-run 
imprecision . . The within-run coefficient of variation 
varied from 3.74 to 7.75 per cent and the between-run 
coefficient of variation varied from 4.24 to 16.6 per 
cent. 
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n mean (s.d. ) c.v. % 
Within-run 
Std. 20 16 20.74 (1.61) 7.75 
Std. 60 16 54.23 (3.25) 6.00 
Std. 80 16 82.91 (3.10) 3.74 
Between-run 
Std. 20 14 19.73 (3.27) 16.60 
Std. 60 14 53.86 (5.68) 10.55 
Std. 80 7 81.84 (3.39) 4.24 
Table 3.2 Total plasma homocysteine imprecision studies 
3.6.3 Recovery 
Table 3.3 shows the results of recovery studies obtained 
by spiking plasma standards to obtain the assigned 
concentr~tions. For each concentration 10 plasma samples 
were spiked. Only the mean of the observed values are 
shown . . The recoveries ranged from 90.8% to 109.9%. 
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Std. 20 Std. 60 Std. 80 
Observed value 20.53 54.46 87.88 
Expected value 20.00 60.00 80.00 
Recovery % 102.70 90.80 109.90 
Table 3.3 Total plasma homocysteine recovery studies 
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CHAPTER FOUR 
Results 
4.1 The pre- and post-methionine loading plasma 
homocysteine concentrations in patients and controls 
One control subject had the pre-methionine load plasma 
homocysteine concentration above the mean plus 2.5 and 3 
SD and another had the post-methionine load plasma 
homocysteine concentration above the mean plus 2.5 and 3 
SD of the grouped control data. Thus, the data in 
patients was compared with that in controls before and 
after removing the control 'outliers
' 
above 2.5 SD and 
recalculating the mean. 
·Table 4.1 shows the pre- and post-methionine loading 
homocysteine concentrations in plasma of controls and 
patients and the amount by which amino acid levels 
increased after the load. 
The mean homocysteine concentration was significantly . 
higher in patients than in controls both in the pre- and 






two, both with and without the two control outliers. 
Homocysteine concentration ( tnllol/L) 
pre-loading .. post-loading rise after 
methionine 
mean (SD) mean (SD) mean (SD) 
Patient 16.0 ( 3 .9) 41.1 (14.8) 25.0 (13.3) 
n=32 
Control 11.6 ( 3 .5) 28.4 ( 7 .0) 16.8 ( 5 .0) 
n=21 ** 
p . 0.0000 0.0001 0.0021 
Patient 16.0 (3.9) 41.1 (14.8) 25.0 (13.3) 
n=32 
Control 12.4 ( 4 . 5 ) 30.0 ( 8 . 5 ) 17.6 ( 6 .0) 
n=23 * 
p 0.004 0.0007 0.0044 
* including all controls 
** 
without two controls, one with the fasting 
hyperhomocysteinaemia above the control mean 
+2~5 and 3 SD and one with post-methionine 
hyperhomocysteinaemia above the control mean 
+ 2.5 and 3 SD 
Table 4.1 The pre- and post-methionine loading 
plasma homocysteine concentrations and the 
rise in the homocysteine concentrations 
after methionine in patients and controls 
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4.2 The frequency distributions of hyperhomo-
cysteinaemia in patients and controls 
4.2.1 The distributions of homocysteinaemia in 
patients and controls 
Figs. 4.1, 4.2 and 4.3 show the distribution of the 
fasting and post-loading homocysteine concentrations, and 
the response to methionine in patients and controls. The 
distributions were not Gaussian. 
4.2.2 The frequency distributions of fasting hyper-
homocysteinaemia in patients and controls 
Table 4.2 shows the number and percentage of patients 
with pre-load plasma homocysteine levels above the mean 
+ 2, 2.5 or 3 SD of the control group with and without 
removing the two control subjects with hyperhomo-
cysteinaemia from the group. There was no significant 
statistical difference in the distribution of 
homocysteinaemia although a tendency was noted towards 
more frequent hyperhomocysteinaemia in patients both wi th 
and without removing the two controls as described 
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Fig. 4.1 The distribution of the fasting plasma 
homocysteine concentrations in patients 
and controls 
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, Fig. 4.3 The distribution of the methionine 
tolerance in patients and controls 
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p = 0.1902 
p = 0.6665 
P = 0.8671 
Table 4.2 






(21.9%) 6 (18.8%) 
(4.8%)a 1 {4.8%)b 
(12.S%) 0 (0.0%) 
{4.3%)d 1 {4.3%)e 
p = 0.2908 
p = 0.5742 






The frequency of fasting hyperhomo-
cysteinaemia in patients and controls 
cas z: 
4.2.3 The frequency distributions of post-methionine 
hyperhomocysteinaemia in patients and controls 
Table 4.3 shows the number and percentage of patients 
with post-load plasma homocysteine levels above the mean 
+ 2, 2.5 or 3 SD of the control group with and without 
removing the two controls with hyperhomocysteinaemia. 
Although there was no statistically significant 
difference in the distribution of hyperhomocysteinaemia 
between the two groups when all the controls were 
included, there was a tendency to a higher homocysteine 
levels in patients since 25.0 and 18.8 % had raised 
homocysteine levels, compared to 8.7 and 4.3 % in 
controls, at the 2 and 2.5 SD cutoff points. On removing 
the two controls as described earlier, a significant 
difference was noted in the distribution at the 2 and 2.5 
SD cutoff values with 40.6 and 28.1 % of patients having 
hyperhomocysteinaemia compared to none in the control 
group. At the 3 SD cutoff point 18.8% of patients had 
hyperhomocysteinaemia, compared to none in controls, but 
the difference was not statistically significant. 
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Homocysteine Conc. greater than 









p = 0.0024 
P = 0.0961 










p = 0.0218 
p = 0.2333 





The frequency of post-met~ionine loading 
hyperhomocysteinaemia in- patients and 
controls 
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4.2.4 The frequency distributions of the abnormal 
methionine tolerance in patients and controls 
Table 4.4 shows the number and percentage of patients 
wi th abnormal methionine tolerance (abnormal rise in 
homocysteine after methionine loading) with and without 
removing control subjects with hyperhomocysteinaemia from 
the control group. 
There was no significant difference between the results 
between the groups when all the controls were included, 
although more patients than controls had abnormal 
methionine tolerance. On removing the controls as 
described earlier, the difference between the pre- and 
post-methionine loading homocysteine concentrations was 
above the mean plus 2 and 2.5 SD of the control value in 
34.4% and 21.9% of patients and in none of the controls. 











p = 0.0075 
P = 0.1547 
p :: 0.5742 
Table 4.4 






(34.4%) 7 (21.9%) 
(O.O%)a 0 (O.O%)b 
(21.9%) 4 (12.5%) 
(4.3%)d 1 (4.3%)e 
b 
d 
p = 0.0593 
P = 0.1525 






Frequency of abnormal methionine tolerance 
in patients and controls 
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4. 3 The frequency distributions of hypertension and 
hyperlipidaemia in controls and, including smoking, in 
patients without ,and with hyperhomocysteinaemia 
In most publications the cutoff value for homo-
cysteinaemia in patients was taken as the mean +2 SD of 
the mean control level after removing control outliers 
and recalculating the mean. In this study the cutoff 
value was taken at above 2.5 SD of the recalculated mean 
in controls, and was thus stricter and included 6 (18.8%) 
patients with fasting, 9 (28.12%) patients with post-
me thionine load hyperhomocys teinaemia, 7 (21. 9%) pa tien ts 
with methionine intolerance and one control (4.8%) with 
fasting hyperhomocysteinaemia. 
4 .3. 1 . The frequency distribution of hypertension and 
hyperlipidaemia in patients and controls 
Table 4.5 shows the frequency distribution of 
hypertension and hyperlipidaemia in patients "and in 
controls. There was a preponderance of males in both 
groups. This could not "be avoided because all subjects 
who fulfilled " the entry criteria and agreed to the 




the gender, and males predominated. There was no 
significant statistical difference in the distribution of 
hyperlipidaemia or hypertension between the groups. 
However, in both controls and patients there was a high 
(but similar) frequency of hypercholesterolaemia. 
Further, twice more pa tients had raised triglycerides 
than controls. Hypertension, was, though, twice more 














Patients Controls P 
N/Total % N/Total % 
7/32 21.9 9/21 42.9 0.1863 
21/32 65.6 13/21 61.9 0.9868 
9/32 28.1 3/21 14.3 0.3998 
27/32 84.4 17/21 81.0 0.9606 
5/32 15.6 4/21 19.0 0.9606 
6/32 18.8 1/21 4.8 0.2908 
9/32 28.1 0/21 0 0.0218 
7/32 21.9 0/21 0 0.0593 
The frequency distribution of hypertension 
and hyperlipidaemia and the gender 
distribution in patients and controls 
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4.3.2 The frequency distributions of hyperlipidaemia, 
hypertension, smoking and gender in patients with 
vascular disease with and without hyperhomocysteinaemia 
Table 4.6 shows the frequency distribution of 
hyperlipidaemia, hypertension and smoking, as well as the 
gender distribution in patients with and without post-
methionine hyperhomocysteinaemia. There was no 
significant difference in the distribution of 
hypertension or hyperlipidaemia although . raised 
triglycerides were more frequent in patients with 
hyperhomocysteinaemia. Smoking was . significantly more 
frequent in hyperhomocysteinaeulics. Further all patients 
with hyperhomocysteinaemia who were smokers, were also 
males. 
Note -- at the time of the study, the data on the smoking 
habits in controls was not thought accurate and is, thus, 











Patients with vascular disease 
hyper- normo-homocysteinaemia 
homocysteinaemia 
N/Total % N/Total % p 
7/9 77.8 14/23 60.9 0.6231 
4/9 44.4 5/23 21.7 0.3969 
2/9 22.2 5/23 21.7 0.6557 
9/9 100.0 11/23 47.8 0.0195 
9/9 100.0 18/23 78.3 0.3264 
0/9 0.0 5/23 21.7 0.3264 
. The frequency distribution of 
hyperlipidaemia, hypertension, smoking and 
gender in patients with vascular disease 
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4.4 The comparison of the age, haematological and 
biochemical indices and the blood pressure between the 
patients and controls 
4.4.1 The comparison of the patients' age at 
presentation and plasma lipids following recovery from 
the acute episode with those in controls at the time of 
methionine loading 
Since some patients were tested several years after the 
original presentation wi th vascular diseases and had been 
on lipid or hypertension lowering treatment, a comparison 
was made, where possible, between the age at first 
presentation, the fasting blood lipi4s after the acute 
episode but before any treatment was instigated, in 
patients, and in controls during methionine loading. The 
blood pressure indices were not compared because of their 
variability. 
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Table 4. 7 shows the comp'arison of the age and the lipid 
concentrations in the patients at first presentation and 
in controls during the methionine loading test. There 
was no difference in the concentration of cholesterol ' but 
there was in the concentration of triglycerides, which, 





patients controls p 
mean (SD) n mean (SO) n 
50.62(5.7) 32 44.2{6.7) 21 <0.05 
5.87(1.3) 25 5.51(0.89) 21 >0.05 
1.77(0.8) 21 1.26{0.7) 21 <0.05 
Age and lipid concentrations in patients 
' and controls 
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n 
4.4.2 The comparison of the age at presentation and 




Trig. (mmo l/L) 
Table 4.8 
Patients with vascular disease 
hyperhomo- normohomo-
cysteinaemia cysteinaemia 
mean (SD) n mean (SD) n p 
53.9 ( 5 .9) 9 55.9 ( 7 . 2 ) 23 0.4608 
6.20 ( 1 .8) 9 5.7 ( 1 .0) 23 0.3200 
2.20 ( 2 . 4 ) 9 1.4 (0.8). 23 0.1440 
The age and plasma lipids concentrations 
in patients at presentation 
The age and plasma lipids concentrations at presentation 
in patients with and without hyperhomocysteinaemia are 
shown in Table 4.8. There were no significant 
differences between the two groups. 
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4.4.3 The comparison of the B12 , serum folate and RBC 
folate in patients and controls at the time of 
presentation 
The B12 , serum folate and red blood cell folate at the 
time of methionine loading are shown in Table 4.9. There 







patient control p 
329+121 339+86 >0.05 
26.9+9.6 21.65+9.7 >0.05 
657+242 538+273 >0.05 
The B12 , serum folate and red blood cell 
folate between patients and controls 
The other haematological and biochemical indices are not 
shown, as there were no significant differences between 
the patients and controls. However, 2 patients had 
borderline raised bilirubin and alanine amino transferase 
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activities, which were, thought not to be significant 
enough to affect homocysteine metabolism, and which were 
only noted in subjects with unremarkable pre- and post-
methionine load plasma homocysteine levels. 
4.4.4. The comparison of the B12 , serum folate and RBC 
folate levels in patients with and without 
hyperhomocysteinaemia and in controls 
Controls Patients 
RBC folate re·duced n % of n % of p 
all all 
All Subj'ects 8 38.1 5 15.6 0.1252 
Subjects with 




raised post-load 2 9.5 ·2 6.3 0.1407 
homocysteine 
levels 
Table 4.10 The frequency distribution of low and 
normal RBC folate concentrations in 
controls and patients with 'normal' and 
raised homocysteine levels 
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Table 4.10 shows . the frequency distribution of low and 
normal RBC folate concentrations in controls and patients 
with 'normal' and raised homocysteine levels. Only one 
control, with 'normal' homocysteine levels, had a s~rum 
B12 level below the lower limit of the reference range. 
The serum folate was normal in all subjects. Eight 
controls had low RBC folate levels which were associated 
with 'normal' homocysteine levels in five, a raised 
fasting homocysteine level in .one and an abnormal 
response to methionine in two. Five patients had reduced 
RBC folate levels, of which in two the fasting 
homocysteine lev~ls was raised and in two the response to 
methionine was abnormal. On statistical analysis, there 
were no differences in the frequency of low RBC folate in 
controls and patients nor in patients with normal and 






The method we used for homocysteine measurement involves 
a number of manual preparation steps such as sample 
~eduction, protein precipitation and derivatization. 
These procedures introduced inherent random errors 
affecting the precision of the assay. Further, the 
internal standard used, 2-mercaptopropionyl glycine gave 
broad, late eluting internal standard peaks which made 
quantitation difficult. Birta et al. (50) obtained 
sharp, well separate peaks with the same internal 
standard, but their separation conditions and sample 
preparation steps were different and could not be 
incorporated in this study. Other workers even measured 
homocysteine without an internal standard (49). 
The assay had acceptable within-run precision, with the 
coefficient of variation varying from 3.74% to 7.75%. 
The between-run precision was poorer, wi th coefficient of 
variation varying from 4.24% to 16.6%. Although the 
within-batch imprecisi·on 
published methods (49, 
was comparable to 
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slightly poorer. ' However, for the purpose of this study 
all data, including occasional outliers, was included. 
If a better internal standard ·could have been obtained, 
the imprecision may have been improved. 
The method had good linearity from 0 to at least 100 
umol/L. Linear regression analysis yielded y=O .'0193x-
0.0692 where y was the peak height ratio of homocysteine 
to internal standard, x the concentration of homocysteine 
and the correlation coefficient 0.995. In heterozygous 
homocysteinaemia, after methionine loading, the 
homocysteine concentration seldom increases to more than 
100 urnol/L. Therefore the linearity range obtained in 
this study was tho~ght acceptable for homocysteine 
measurements to identify heterozygotes. 
The recovery of homocysteine, added to serum samples was 
101.1% (S.D.=9.7). This compared favourably with the 
other report ·using 
fluorobenzo-2-oxa-l,3 
. (104.3±5.4%) (51). 




Homocysteinaemia in patients and controls 
Hyperhomocysteinaemia is usually due to cystathionine ~_ 
synthase deficiency. Homozygous homocysteinaemia is 
rare, but may, in the heterozygous state affect up to 1 
in 70 to 1 in 200 general population (19). Cystathionine 
~-synthase deficiency blocks the transsulfuration pathway 
from methionine to cysteine, resulting in homo-
cysteinaemia. Defects in vitamin B12 and folate 
dependent remethylation of homocysteine constitute other 
rare causes of inheri ted hyperhomocysteinaemia (18). 
Liver disease and drugs which affect the metabolism of 
methionine are also aetiological factors for 
hyperhomocysteinaemia (1). Fasting homocysteine levels 
are reported raised in homozygous homocysteinaemia, in 
defects in vi tamin B12 and folate metabolism but are 
normal with vitamin B6 deficiency and in heterozygotes 
homocysteinaemia (19). However, after methionine 
loading, cobalamin deficient patients and patients with 
m~thylenetetrahydrofolate reductase de,ficiency are 
reported to have normal increases in plasma homocysteine 
levels, whereas patients who are homozygous or obligate 
heterozygotes for cystathionine ~ -synthase deficiency 
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show an abnormal response (9). Thus, by measuring the 
fasting and post-methionine loading homocysteine 
concentrations, one - should be able to differentiate 
whether the cause of hyp'erhomocysteinaemia is due to 
defects in vitamin metabolism or due to cystathionine ~_ 
synthase insufficiency. In our study, therefore, the 
fasting and post-methionine loading homocysteine 
concentration were measured. 
Boers and co-wp rker (19) measured the post-methionine 
loading free homocysteine levels in post-menopausal women 
and observed them to be higher than in pre-menopausal 
women, while later Lars Brattstr3m (17) found no such 
difference in the total plasma homocysteine levels and 
suggested that measurement of the total homocysteine 
concentration would better discriminate between 
heterozygotes for homocystinuria and . normal subjects, 
especially in women. Therefore, in our study, where both 
men and women were included, · we measured total 
homocysteine concentrations. 
The association of hyperhomocysteinaemia with athero-
sclerosis and predisposi tion to venous and arterial 
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thromboembolism. in homozygous hyperhomocysteinaemia is 
well known and is thought to be due to raised levels of 
homocysteine (20). Increased risk, for vascular disease 
is suggested also in heterozygotes (18). In 1985, Boers 
et al. (19) showed that a large proportion of patients 
with cerebral or peripheral occlusive vascular disease 
responded to methionine loading wi th abnormally high 
homocysteine concentrations, which were within the same 
range as found in obligate heterozygotes for 
homocystinuria due to cystathionine ~ -synthase 
deficiency. As a low activity of the enzyme was also 
found in the cultured skin fibroblasts from all their 
patients with an abnormal response to methionine, Boers 
et al. (19) considered them to be heterozygotes for 
cystathionine ~-synthase deficiency and suggested that 
. the methionine loading test could detect most 
heterozygotes. 
Since the reference range for normal homocysteine levels 
is no.t fully established yet, in most studies where 
homocysteine was measured in patients with vascular 
disease, the amino acid was also measured in controls, 
and various cutoff values were used to distinguish 
91 
hyperhomocysteinaemia from normohomocysteinaemia. Boers 
and Andersson (17) first removed control outliers with 
homocysteine concentrations in the fasting state or an 
after loading which exceed the mean + 3 SD, recalculated 
the mean and used the new mean + 2 · SD as their cutoff 
values. In our study we also used the control mean + 3 
SD to remove the control outliers (the same patients were 
outliers at 2.5 and 3 SD) but after recalculating the 
mean, we took the new mean + 2.5 SD as the cutoff value, 
thus slightly stricter criteria than in the study of 
Boers and Andersson. Based on this, six out of 32 
patients had fasting hyperhomocysteinaemia, giving the 
incidence of 18.8%, while in controls the incidence (one 
subject) was 4.8%. The frequency distribution between 
the two groups was thought not statistically differen~. 
In Boers' study, fasting homocysteinaemia was found only 
in two out of twenty premenopausal heterozygote patients 
giving a 10% incidence,but no significant difference was 
found in other subjects. 
Al though the frequency distribution of fasting hyper-
homocysteinaemia was not statistically different between 




concentration was significantly higher in the patient 
groups (16.0 ± 3.9 umol/L) than in the controls (11.6 ± 
3.5 umol/L). This is different from a previous report 
where no differences were found between patients' and 
controls (19). 
The incidence of hyperhomocysteinaemia after methionine 
loading (with post-methionine homocysteine concentration 
greater than 45.9 umol/L and after two of the control 
outliers were excluded) was 28.1% in patients and 0% in 
controls. This frequency distribution was significantly 
different between the groups and similar to that found in 
Boers' study, where an incidence of 28% in a group of 50 
Western patients was found. Thus, in this first study in 
the Chinese population, the incidence of hyper-
homocysteinaemia in patients with vascular ~isease 
appears to be the same as that in the Western population. 
In the control group there was one subject with fasting 
hyperhomocysteinaemia and one with post-methionine 
hyperhomocysteinaemia above 3 SD before removing them as 
outliers, giving an incidence of 4.3% for each. Further, 
after removing the outliers, there was still one control 
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with a fasting homocysteine concentration above 2.5 SD 
(thus total 8.7%). This was higher than previously 
reported ~ - ( 0% for fasting and 2.5% for post-methionine 
loading (19). 
Most studies measure the pre- and post-methionine load 
concentrations (17,19,48). We also compared the 
difference between pre- and post-methionine loading 
homocysteine concentrations because the fasting state 
level depends on a number of factors such as the vitamin 
status while the post-load state must depend at least 
partly on the fasting level. Thus it was thought that 
the difference between the two levels may better reflect 
the adequacy of enzyme activity than the post-load level 
alone. 
As with the post-methionine homocysteine concentration, 
methionine intolerance was significantly different both 
as frequency distribution' and as actual levels, between 
the patients and controls. However, a1 though fewer 
patients had methionine intolerance than had raised post-
methionine levels, the discriminating value of this index 
was less than was hoped. It had been expected that in 
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patients with raised post-methionine homocysteine levels 
and the 'normal' difference between the pre- and post-
,Joad levels, raised fasting levels and vitamin 
deficiencies would be obtained. This was not, however, 
usually the case. 
No subject had reduced plasma folate. The B12 was 
reduced in one control only, who had normal homocysteine 
levels. In addition, twice as many controls had reduced 
RBC folate levels (38.1%) as patients (15.6%), and in 
both groups, this was associated with raised fasted 
homocysteine levels only in the minori ty. Thus, al though 
a larger proportion of patients than controls had raised 
fasting homocysteine levels, this did not appear to be 
because of B12 or folate deficiency. Therefore, in 
patients with raised fasting homocysteine levels,· 
heterozygous hyperhomocysteinaemia was more likely 
although the diagnosis of the heterozygous state should 
'be confirmed by measuring the enzyme, at least, until the 
reference range for the three indices used in the studies 
is established with a larger sample population. 
There was no statistically significant difference in the 
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occurrence of hypertension and hyperlipidaemia between 
patients and controls, nor between patients with 'normal' 
and raised post-methionine homocysteine levels. However, 
the incidence of hypercholesterolaemia was high in both 
patients and controls, hypertension twice more frequent 
in controls and raised triglycerides twice more common in 
patients. Raised triglycerides were also twice more 
frequent in patients with than without hyperhorno-
cysteinaemia. 
However, on comparison of the actual levels, though both 
the cholesterol and triglycerides concentration were 
higher in patients with hyperhomocysteinaemia than in 
controls, only the latter was highly significant, 
suggesting that hyperhomocysteinaemia may be mainly an 
independent risk factor, although it may interact 
slightly with hypertriglyceridaernia, in the pathogenesis 
of vascular disease. 
In conclusion, the results of this study showed that 
there is a similarly high incidence of mild hyper-
homocysteinaeluia in patients with premature occlusive 
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vascular disease in the Chinese as in other populations 
and that hyperhomocysteinaemia may be an important risk 
factor for premature occlusive peripheral arterial or 
cerebrovascular disease. This deserves attention. If 
further studies establish that homocysteine lowering 
treatment may prevent the progression of the arterio-
sclerotic lesions or to prevent the occurrence of 
premature occlusive vascular disease, particularly where 
there is an absence of other risk factors for athero-
sclerosis, investigation for mild hyperhomocysteinaemia 
may become as important as detection of hypertension or 
hyperlipidaemia in the prevention of premature vascular 
coronary artery disease. 
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